Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | THRB | P10828 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13500010 | 1.00 | MEN1 (0.74) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL5434893 | 0.97 | TSHR (0.71) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL11081210 | 0.97 | TSHR (0.71) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL29098933 | 0.97 | TSHR (0.71) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL9083720 | 0.97 | TSHR (0.71) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL822812 | 0.97 | TSHR (0.71) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL4392282 | 0.97 | TSHR (0.71) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL874676 | 0.97 | TSHR (0.71) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL2532324 | 0.97 | TSHR (0.71) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL8813644 | 0.95 | MEN1 (0.82) | MEN1KMT2ATHRBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| US-7601746-B2 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | MPL, TEK, GHRHR | MEN1 534/4885KMT2A 3732/4885THRB 92/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | MEN1 245/4885KMT2A 1294/4885THRB 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.